Avadel Pharmaceuticals (AVDL) Short term Debt: 2009-2022
Historic Short term Debt for Avadel Pharmaceuticals (AVDL) over the last 10 years, with Sep 2022 value amounting to $26.3 million.
- Avadel Pharmaceuticals' Short term Debt was N/A to $26.3 million in Q3 2022 from the same period last year, while for Sep 2022 it was $26.3 million, marking a year-over-year change of. This contributed to the annual value of $5.6 million for FY2019, which is 41.16% down from last year.
- According to the latest figures from Q3 2022, Avadel Pharmaceuticals' Short term Debt is $26.3 million, which was up 0.22% from $26.2 million recorded in Q2 2022.
- In the past 5 years, Avadel Pharmaceuticals' Short term Debt registered a high of $26.3 million during Q3 2022, and its lowest value of $5.6 million during Q4 2019.
- For the 2-year period, Avadel Pharmaceuticals' Short term Debt averaged around $21.1 million, with its median value being $26.2 million (2022).
- Data for Avadel Pharmaceuticals' Short term Debt shows a maximum YoY slumped of 65.37% (in 2018) over the last 5 years.
- Avadel Pharmaceuticals' Short term Debt (Quarterly) stood at $9.4 million in 2018, then plummeted by 41.16% to $5.6 million in 2019, then crashed by 37.65% to $5.9 million in 2020, then reached $26.3 million in 2022.
- Its Short term Debt stands at $26.3 million for Q3 2022, versus $26.2 million for Q2 2022 and $26.2 million for Q1 2022.